TY - JOUR
T1 - Refractory lympho-epithelial carcinoma of the nasopharynx
T2 - a case report illustrating a protracted clinical course.
AU - Wu, Frederick Y.
AU - Yang, Eddy S.
AU - Willey, Christopher D.
AU - Ely, Kim
AU - Garrett, Gaelyn
AU - Cmelak, Anthony J.
PY - 2009
Y1 - 2009
N2 - Nasopharyngeal carcinoma is an uncommon cancer in North America. Its clinical course is typified by locally advanced disease at diagnosis and has a high propensity for both regional and distant spread. It is, therefore, typically treated with a combination of radiation and chemotherapy. This report describes our 10-year clinical and radiological findings in a 48-year-old Vietnamese male patient with locally-advanced T4N1M0 lympho-epithelial carcinoma of the nasopharynx. Despite a long remission period after his initial course of aggressive chemoradiation, his tumor recurred locally after 4 years. Thereafter, throughout a period of over 10 years, he has been treated with multiple courses of re-irradiation and three different trials of chemotherapy. He was ultimately provided with over 30 months of progression-free tumor control with the epidermal growth factor receptor (EGFR)-inhibitor cetuximab. This case illustrates the commonly protracted course of this disease and its responsiveness to multiple treatment modalities.
AB - Nasopharyngeal carcinoma is an uncommon cancer in North America. Its clinical course is typified by locally advanced disease at diagnosis and has a high propensity for both regional and distant spread. It is, therefore, typically treated with a combination of radiation and chemotherapy. This report describes our 10-year clinical and radiological findings in a 48-year-old Vietnamese male patient with locally-advanced T4N1M0 lympho-epithelial carcinoma of the nasopharynx. Despite a long remission period after his initial course of aggressive chemoradiation, his tumor recurred locally after 4 years. Thereafter, throughout a period of over 10 years, he has been treated with multiple courses of re-irradiation and three different trials of chemotherapy. He was ultimately provided with over 30 months of progression-free tumor control with the epidermal growth factor receptor (EGFR)-inhibitor cetuximab. This case illustrates the commonly protracted course of this disease and its responsiveness to multiple treatment modalities.
UR - http://www.scopus.com/inward/record.url?scp=77957931561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957931561&partnerID=8YFLogxK
U2 - 10.1186/1758-3284-1-18
DO - 10.1186/1758-3284-1-18
M3 - Article
C2 - 19527509
AN - SCOPUS:77957931561
SN - 1758-3284
VL - 1
SP - 18
JO - Head & neck oncology
JF - Head & neck oncology
ER -